Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aldosterone: cardiovascular assault.

Allan D Struthers1

  • 1Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, Scotland. a.d.struthers@dundee.ac.uk

American Heart Journal
|November 8, 2002
PubMed
Summary

Aldosterone contributes to cardiovascular damage through various mechanisms. Aldosterone receptor blockade can reverse these effects, reducing cardiovascular morbidity and mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of bradykinin receptor 2 (BDKRB2) variants with physical performance and muscle mass: Findings from the LACE sarcopenia trial.

PloS one·2024
Same author

Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation.

Health technology assessment (Winchester, England)·2024
Same author

Activin type I receptor polymorphisms and body composition in older individuals with sarcopenia-Analyses from the LACE randomised controlled trial.

PloS one·2023
Same author

ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.

PloS one·2023
Same author

Impact of beta-blockers on mortality and cardiovascular disease outcomes in patients with obstructive sleep apnoea: a population-based cohort study in target trial emulation framework.

The Lancet regional health. Europe·2023
Same author

Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.

Lancet (London, England)·2022

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Angiotensin-converting enzyme inhibitors improve cardiovascular outcomes but are limited by aldosterone escape.
  • Aldosterone plays a significant role in cardiovascular morbidity and mortality.

Purpose of the Study:

  • To elucidate the mechanisms by which aldosterone contributes to cardiovascular damage.
  • To evaluate the therapeutic potential of aldosterone receptor blockade.

Main Methods:

  • Review of in vitro and in vivo studies.
  • Analysis of aldosterone's effects on cardiovascular system.

Main Results:

  • Aldosterone induces vasculopathy, endothelial dysfunction, and reduced fibrinolysis, leading to organ damage.
  • Aldosterone promotes myocardial hypertrophy, fibrosis, autonomic imbalance, and electrolyte abnormalities, increasing risk of heart failure and sudden cardiac death.
  • Aldosterone receptor blockade reverses these deleterious effects, reducing cardiovascular morbidity and mortality by an additional 30% when added to standard therapy.

Conclusions:

  • Selective aldosterone blockers like eplerenone show promise in reducing cardiovascular morbidity and mortality.
  • Further investigation into the role of eplerenone in cardiovascular disease is warranted.

Related Experiment Videos